UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD

Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.

GKT831: A novel PII anti-fibrotic small molecule
Alexandre Grassin talks about GKT831, a NOX1 and NOX4 inhibitor. GKT831 is evaluated in phase 2 clinical trials in primary
biliary cholangitis (PBC) and in an investigator-initiated Phase 2
clinical trial in Type 1 Diabetes and Kidney Disease (DKD).

View the slides

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.

View the slides

Genetics of progressive nonalcoholic fatty liver disease
Hepatic fat accumulation and nonalcoholic fatty liver disease (NAFLD), especially the progressive form of the disease, have a strong heritable component. Luca Valenti discusses I148M variant of PNPLA3 is the main common genetic determinant of NAFLD.

View the slides

Want to read more on NASH and NAFLD? Good news! Our resources page is packed full of slides and presentation videos, why not take a look now?

Leave a Reply

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive